Paperpal Prime Logo

Rheumatology and Therapy : Impact Factor & More

eISSN: 2198-6584pISSN: 2198-6576
JournalOpen Access

Key Metrics

CiteScore
4.1
H-Index
29
Impact Factor
< 5
SJR
Q1Rheumatology
SNIP
1.31
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Rheumatology and Therapy

Rheumatology and Therapy Journal Specifications

Overview
Publisher SPRINGER
Language English
Frequency Quarterly
Article Processing ChargesEUR 5500 | USD 6850 | GBP 4700
Publication Time6
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyQuarterly
Publication Start Year2014
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 6
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY-NC
OA statementVisit website
View less

Planning to publish in Rheumatology and Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Rheumatology and Therapy

Patient-Reported Disease Activity, Health-Related Quality of Life, and Coping in Systemic Lupus Erythematosus: A Cross-Sectional Online Survey in Switzerland (Lupus-IMPACT)
  • 25 Oct 2026
  • Rheumatology and Therapy
Bimekizumab in Chinese Patients with Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results from the Phase3 BEMOBILE1 Study.
  • 23 Oct 2026
  • Rheumatology and therapy
Impact of the Sociodemographic Index on Efficacy/Safety of Tofacitinib in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Phase 2/3/3b/4 Studies.
  • 16 Oct 2026
  • Rheumatology and therapy
Effectiveness of Newly Initiated Tofacitinib and Biologic DMARDs in Patients with Rheumatoid Arthritis.
  • 15 Oct 2026
  • Rheumatology and therapy
Long-Term Safety and Efficacy of Upadacitinib in Patients with Psoriatic Arthritis: 5-Year Results from the Phase3 SELECT-PsA1 Study.
  • 7 Oct 2026
  • Rheumatology and therapy
Sociodemographic and Clinical Determinants of Colchicine Adherence in Adults with Familial Mediterranean Fever: A Cross-Sectional Study
  • 25 Sep 2026
  • Rheumatology and Therapy
Patient-Reported Disease Activity, Health-Related Quality of Life, and Coping in Systemic Lupus Erythematosus: A Cross-Sectional Online Survey in Switzerland (Lupus-IMPACT)
  • 25 Oct 2026
  • Rheumatology and Therapy
Bimekizumab in Chinese Patients with Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results from the Phase3 BEMOBILE1 Study.
  • 23 Oct 2026
  • Rheumatology and therapy
Impact of the Sociodemographic Index on Efficacy/Safety of Tofacitinib in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Phase 2/3/3b/4 Studies.
  • 16 Oct 2026
  • Rheumatology and therapy
Effectiveness of Newly Initiated Tofacitinib and Biologic DMARDs in Patients with Rheumatoid Arthritis.
  • 15 Oct 2026
  • Rheumatology and therapy
Long-Term Safety and Efficacy of Upadacitinib in Patients with Psoriatic Arthritis: 5-Year Results from the Phase3 SELECT-PsA1 Study.
  • 7 Oct 2026
  • Rheumatology and therapy
Sociodemographic and Clinical Determinants of Colchicine Adherence in Adults with Familial Mediterranean Fever: A Cross-Sectional Study
  • 25 Sep 2026
  • Rheumatology and Therapy

FAQs on Rheumatology and Therapy